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oes Enoxaparin Have Enough
INESSE to Replace
nfractionated Heparin in
rimary Percutaneous
oronary Intervention?*
haun G. Goodman, MD, MSC
oronto, Ontario, Canada
cute ST-segment elevation myocardial infarction (STEMI)
s caused by coronary plaque disruption with exposure of
ubstances that promote platelet activation, adhesion, and
ggregation; thrombin generation; and thrombus formation
eading to an occluded infarct-related artery (IRA) (1).
hus, patients presenting with STEMI receive reperfusion
herapy—either fibrinolysis or primary percutaneous coro-
ary intervention (PCI)—to restore coronary flow, limit
yocardial necrosis, and improve clinical outcomes (2–4).
ven if adequate restoration of flow with reperfusion
herapy is established in the epicardial IRA, perfusion of the
nfarct zone might still be compromised. Microvascular
amage occurs in part as a consequence of downstream
mbolization of platelet microemboli and thrombi followed
y release of substances from activated platelets that pro-
ote occlusion or spasm. Adjunctive antithrombotics are
herefore critical to maintain IRA patency (decreasing
hrombus accretion and preventing reocclusion) and poten-
ially minimize microvascular damage (2).
See page 203
The vast majority of clinical trial evidence supporting
uideline recommendations (2–4) for the use of antiplatelet
nd anticoagulant therapies in STEMI has come from
atient populations receiving fibrinolytic therapy; however,
rimary PCI has been demonstrated to be superior to
brinolysis in reducing mortality when it can be performed
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ventis, GlaxoSmithKline, and The Medicines Company.apidly (5), such that primary PCI is the preferred reperfu-
ion strategy whenever feasible (3,4). Importantly, the goals
f antithrombotic therapy for primary PCI differ somewhat
rom those for fibrinolysis, which fails to restore IRA
atency or is associated with a risk for early reocclusion in
pproximately 20% of patients (6); the main focus of
nticoagulant therapy in primary PCI is the minimization of
hrombotic complications related to the mechanical inter-
ention. Although unfractionated heparin (UFH) is the
nly Class/Grade I-recommended acute anticoagulant ther-
py in primary PCI (2–4), the weight/level of evidence is
C,” reflecting mainly a consensus of opinion of the experts
ather than guidance from randomized trial data.
Potential alternatives to UFH in STEMI patients under-
oing PCI have been explored. The indirect factor Xa
nhibitor fondaparinux was compared with UFH in a
ubgroup of STEMI patients undergoing primary PCI in
he OASIS-6 (Organization for the Assessment of Strate-
ies for Ischemic Syndromes-6) study (7), and there was a
umeric increase in the composite of death or reinfarction
mong fondaparinux-treated patients that occurred in the
etting of a higher rate of guiding catheter thrombosis and
ore coronary complications. Thus, in the setting of pri-
ary PCI, fondaparinux is not recommended (2–4).
The direct thrombin inhibitor bivalirudin was compared
ith UFH plus glycoprotein IIb/IIIa inhibitors in patients
ndergoing primary PCI in the HORIZONS-AMI (Har-
onizing Outcomes With Revascularization and Stents in
cute Myocardial Infarction) trial (8). Treatment with
ivalirudin resulted in a significantly lower 30-day rate of
et adverse clinical events, due to a lower rate of major
leeding, but with similar rates of major adverse cardiovas-
ular events (although death at 30 days was significantly
ower). However, the minority of patients received bivaliru-
in monotherapy (6), and although the 30-day net clinical
nd point was relatively reduced in the bivalirudin-treated
atients who received pre-randomization UFH, there was a
elative increase in events in the bivalirudin-treated patients
ho did not receive antecedent UFH. Together with the
ncreased risk for early stent thrombosis, these findings have
ed to a lower class of recommendation for bivalirudin as the
ole anticoagulant in primary PCI (4).
Previously, data in the setting of primary PCI with
noxaparin have been limited to anti-Xa level findings in a
mall prospective registry (9) and clinical trial subgroup
10). Montalescot et al. (11) now provide substantial addi-
ional information regarding enoxaparin in primary and
acilitated PCI (with abciximab or abciximab plus half-dose
brinolysis) as part of a nonrandomized substudy of the
INESSE (Facilitated INtervention with Enhanced Reper-
usion Speed to Stop Events) trial (12). Each enrolling
enter prespecified its choice of either UFH or enoxaparin
s the adjunct anticoagulant therapy; 759 from 42 centers
ere included in the enoxaparin substudy, and 1,693 from
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21470 centers received UFH. There was reasonable adherence
o the intended anticoagulation strategy (e.g., 93% of
atients received enoxaparin) with limited cross-over (e.g.,
% received UFH in addition to enoxaparin).
Because the substudy focused on a nonrandomized com-
arison between enoxaparin and UFH, it is not surprising
hat the 2 “treatment” groups were not comparable. For
xample, UFH-treated patients were more frequently en-
olled at PCI-capable hospitals in Western Europe and had
onger times from symptom onset to balloon; they were also
ore likely to have received aspirin but less likely to have
eceived clopidogrel or ticlopidine before randomization. In
n attempt to adjust for multiple risk factors and potential
mbalance of other factors, logistic regression modeling and
ropensity score methodology were employed.
Nonintracranial hemorrhage major bleeding was lower in
noxaparin-treated patients, but minor bleeding was more
requent. Intracranial hemorrhage was rare and not different
n the 2 groups. Although the FINESSE primary composite
nd point (all-cause mortality or complications of myocar-
ial infarction) through 90 days was similar in the 2
nticoagulant groups, there was a lower risk of the compos-
te of death or reinfarction at 30 days and all-cause mortality
t 90 days with enoxaparin. These findings were particularly
pparent in the subset of patients (n 806) who underwent
rimary PCI; indeed, this might be the most relevant
ubgroup given the lack of benefit and potential harm of the
trategy of facilitated PCI compared with primary PCI (13).
Thus, enoxaparin was associated with a lower risk of
ardiovascular outcomes and major bleeding (but with more
inor bleeding) when compared with UFH in STEMI
atients undergoing primary PCI (11). Importantly, al-
hough the primary safety end points and secondary efficacy
nd points were pre-specified, there was no formal statistical
djustment made for multiple comparisons in this un-
linded, observational, hypothesis-generating substudy. Al-
hough providing the largest experience of enoxaparin in
rimary PCI, the FINESSE substudy does not provide
ractice- or guideline-changing results—indeed, UFH
hould remain the anticoagulant of choice in the setting of
rimary PCI at present. However, Montalescot et al. are
urrently seeking to confirm the hypothesis raised by their
INESSE findings in a randomized, clinical outcome trial
omparing IV enoxaparin (0.5 mg/kg) with UFH (50 to 70
/kg with or 70 to 100 U/kg without glycoprotein IIb/IIIa
nhibition). The ATOLL (Acute STEMI Treated with
rimary angioplasty and intravenous enoxaparin Or UFH to
ower ischemic and bleeding events at short- and Long-erm follow-up) study results are anticipated in late 2010, at Khich time we will learn whether enoxaparin is truly a better
lternative to UFH in primary PCI.
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